Therapeutic Indications

Brolucizumab is indicated for:

Neovascular (wet) age-related macular degeneration (AMD)

Irrespective of gender only Adults (18 years old or older)

Brolucizumab is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (AMD).

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Intravitreal - 6 mg once monthly

Contraindications

Active ingredient Brolucizumab is contraindicated in the following cases:

Ocular or periocular infections

No gender/age discrimination

Patients with active or suspected ocular or periocular infections.

Intraocular inflammation

No gender/age discrimination

Patients with active intraocular inflammation.